Biopharm Co., Directors Sued In Del. Over 'Extreme' Scheme
A five-year run of "extreme and unconscionable self-dealing" has left 62% of Navidea BioPharmaceuticals Inc. equity in the hands of a single stockholder-director, a Delaware Court of Chancery suit has alleged,...To view the full article, register now.
Already a subscriber? Click here to view full article